Aldose Reductase Inhibitor, Epalrestat, Reduces Lipid Hydroperoxides in Type 2 Diabetes

• Published in: ENDOCRINE JOURNAL Vol. 56; no. 1; pp. 149 - 156
• Main Authors: CHIE OHMURA, HIROTAKA WATADA, KOSUKE AZUMA, TOMOAKI SHIMIZU, AKIO KANAZAWA, FUKI IKEDA, TOMOAKI YOSHIHARA, YOSHIO FUJITANI, TAKAHISA HIROSE, YASUSHI TANAKA, RYUZO KAWAMORI
• Format: Journal Article
• Language: Japanese
• Published: The Japan Endocrine Society 2009
• ISSN: 0918-8959

The increased flux of polyol pathway induced by hyperglycemia is implicated in the pathogenesis of various complications associated with diabetic, which results in increased oxidative stress. Because oxidative stress causes tissue damage in patients with diabetes, searching for an effective strategy to reduce oxidative stress in clinical setting is important in order to prevent diabetic complications. The aim of this study was to evaluate the effects of aldose reductase inhibition on oxidative stress in patients with type 2 diabetes mellitus. The subjects of this study were 21 patients with type 2 diabetes. We compared the levels of various oxidative stress markers and antioxidants including plasma thiobarbituric acid-reactive substances, malondialdehyde-modified low-density lipoprotein, vitamin E, β-carotene and lipid hydroperoxides in erythrocytes at baseline with those measured after a 3-month course of epalrestat (150 mg/day), an aldose reductase inhibitor. While administration of epalrestat did not result in significant changes in plasma thiobarbituric acid-reactive substances, malondialdehyde-modified low-density lipoprotein, vitamin E, or β-carotene, it significantly reduced lipid hydroperoxides in erythrocytes. Given the importance of measuring lipid hydroperoxides in erythrocytes as an index of oxidative stress, these results highlight the potential usefulness of epalrestat in reducing oxidative stress in type 2 diabetes mellitus.